...
首页> 外文期刊>Cell death & disease. >P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2
【24h】

P53-induced miR-1249 inhibits tumor growth, metastasis, and angiogenesis by targeting VEGFA and HMGA2

机译:P53诱导的miR-1249通过靶向VEGFA和HMGA2抑制肿瘤生长,转移和血管生成

获取原文
   

获取外文期刊封面封底 >>

       

摘要

MicroRNAs (miRNAs) are important class of functional regulators involved in human cancers development, including colorectal cancer (CRC). Exploring aberrantly expressed miRNAs may provide us with new insights into the initiation and development of CRC by functioning as oncogenes or tumor suppressors. The aim of our study is to discover the expression pattern of miR-1249 in CRC and investigate its clinical significance as well as biological role in CRC progression. In our study, we found that miR-1249 was markedly downregulated in CRC tissues and cell lines, and negatively related to pN stage, pM stage, TNM stage, and overall survival (OS). Moreover, we demonstrated that miR-1249 was a direct transcriptional target of P53 and revealed that P53-induced miR-1249 inhibited tumor growth, metastasis and angiogenesis in vitro and vivo. Additionally, we verified that miR-1249 suppressed CRC proliferation and angiogenesis by targeting VEGFA as well as inhibited CRC metastasis by targeting both VEGFA and HMGA2. Further studying showed that miR-1249 suppressed CRC cell proliferation, migration, invasion, and angiogenesis via VEGFA-mediated Akt/mTOR pathway as well as inhibited EMT process of CRC cells by targeting both VEGFA and HMGA2. Our study indicated that P53-induced miR-1249 may suppress CRC growth, metastasis and angiogenesis by targeting VEGFA and HMGA2, as well as regulate Akt/mTOR pathway and EMT process in the initiation and development of CRC. miR-1249 might be a novel the therapeutic candidate target in CRC treatment.
机译:微小RNA(miRNA)是涉及人类癌症发展的重要功能调节剂,包括结肠直肠癌(CRC)。探索异常表达的miRNA可能通过起癌基因或抑癌作用,为CRC的发生和发展提供新的见解。我们的研究目的是发现miR-1249在CRC中的表达模式,并研究其临床意义以及其在CRC进展中的生物学作用。在我们的研究中,我们发现miR-1249在CRC组织和细胞系中显着下调,与pN阶段,pM阶段,TNM阶段和总体存活率(OS)呈负相关。此外,我们证明了miR-1249是P53的直接转录靶标,并揭示了P53诱导的miR-1249在体内外均抑制肿瘤生长,转移和血管生成。此外,我们证实miR-1249通过靶向VEGFA抑制CRC增殖和血管生成,以及通过靶向VEGFA和HMGA2抑制CRC转移。进一步的研究表明,miR-1249通过靶向VEGFA和HMGA2,通过VEGFA介导的Akt / mTOR途径抑制CRC细胞的增殖,迁移,侵袭和血管生成,并抑制CRC细胞的EMT过程。我们的研究表明,P53诱导的miR-1249可能通过靶向VEGFA和HMGA2抑制CRC的生长,转移和血管生成,并在CRC的发生和发展中调节Akt / mTOR途径和EMT过程。 miR-1249可能是CRC治疗中的新型治疗候选靶标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号